Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · MANGALAM DRUG & CHEM LTD · 6 November 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
MANGALAM DRUG & CHEM LTD
NSE: MANGALAM · BSE: 532637
NSE: MANGALAM · BSE: 532637
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
MANGALAM DRUG & CHEM LTD
StateQ2 FY27 filed
Last close · 6 Nov 2026₹28.87
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · 0.52 · —
MANGALAM DRUG & CHEM LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 369 | 318 | 232 |
| EBITDA (ex other income) | 17 | 36 | (15) |
| margin % | 4.7 | 11.3 | (6.4) |
| Owners' profit | 0 | 0 | 0 |
| EPS, as reported (₹) | (5.73) | 4.25 | (28.05) |
| ROE % · ROCE % | (6.7) · 1.7 | 4.5 · 11.3 | (43.1) · (27.3) |
| Debt / equity (x) | 0.65 | 0.54 | 1.02 |
| Cash from operations | (11) | 43 | 4 |
| Capex | 0 | (20) | (12) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MANGALAM DRUG & CHEM LTD · 6 November 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 89 | 73 | 57 | 107 | 58 | 67 | 57 | 79 |
| Profit before tax | 1 | 2 | (13) | (25) | (10) | (13) | (7) | (9) |
| Net profit | 1 | 0 | (14) | (21) | (10) | (13) | (8) | (7) |
| EPS (₹) | 0.81 | 0.04 | (8.72) | (13.36) | (6.21) | (8.48) | (4.83) | (4.55) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,46,270 | 40.7 | 4.98 | 24.9 | 5.5 | 8.0 | 11.8 | 29.3 |
| DIVI S LABORATORIES LTD | 2,73,493 | 93.6 | 16.32 | 79.4 | 15.3 | 18.8 | 8.7 | 40.7 |
| TORRENT PHARMACEUTICALS L | 1,80,500 | 80.2 | 9.82 | 42.6 | 6.0 | 4.0 | 11.8 | 33.5 |
| LAURUS LABS LIMITED | 1,26,430 | 94.3 | 20.45 | 72.4 | 12.9 | 14.2 | 7.2 | 34.0 |
| ZYDUS LIFESCIENCES LTD | 1,19,550 | 28.8 | 3.94 | 15.4 | 6.4 | 6.8 | 12.4 | 24.0 |
| DR. REDDY S LABORATORIES | 1,14,646 | 40.9 | 2.93 | 18.5 | 3.4 | 4.2 | 12.1 | 19.9 |
| CIPLA LTD | 1,13,988 | 39.3 | 3.21 | 19.3 | 4.6 | 6.2 | 8.0 | 18.7 |
| MANKIND PHARMA LIMITED | 1,04,902 | 46.8 | 5.88 | 30.6 | 7.2 | 7.3 | — | 27.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 0.5 | 3.1 | 8 of 163 | 96% |
| ROCE | (15.7) | 8.0 | 166 of 177 | 6% |
| ROE | (16.9) | 6.8 | 159 of 165 | 4% |
| Debt / Equity | 1.0 | 0.1 | 155 of 166 | 7% |
| EBITDA margin | (1.4) | 14.6 | 156 of 178 | 12% |
| Revenue growth | (25.7) | 17.1 | 142 of 163 | 13% |
| Profit growth | 65.9 | 21.8 | 52 of 157 | 67% |
| Market cap | 46 | 814 | 150 of 181 | 17% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MANGALAM DRUG & CHEM LTD · 6 November 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 6 Nov 2026 · Mangalam Drugs revenue nearly doubles, but September-quarter loss persists | compliance | minimal | — | — |
| 5 Nov 2026 · Quarter ended Sep 2026: consolidated revenue up 61% from year ago, but net loss Rs 721 lakh | results | high | — | — |
| 5 Nov 2026 · September quarter: consolidated revenue rises 61%, but losses and debt risk persist | results | high | — | — |
| 4 Nov 2026 · Annual report and 53rd AGM notice sent to shareholders without email | compliance | minimal | — | — |
| 2 Nov 2026 · Prabhakar Zavar approved as independent director for five years | management changes | medium | — | — |
| 2 Nov 2026 · Postal ballot approves Zavar as independent director for five years | board shareholder meetings | low | — | — |
| 2 Nov 2026 · Prabhakar Zavar approved as independent director for five years | management changes | medium | — | — |
| 29 Oct 2026 · Board to approve September quarter results on November 5 | results | low | — | — |
| 16 Oct 2026 · Bank loan default disclosed to BSE and NSE | credit debt | critical | — | — |
| 7 Oct 2026 · RTA Compliance Certificate filed for Q2 FY27 under SEBI Regulation 74(5) | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in